Cargando…

Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022

BACKGROUND: The reported rate of cardiovascular adverse events (CAE) caused by immune checkpoint inhibitors (ICI) is low but potentially fatal. Assess the risk of CAE in cancer patients and compare the incidence of CAE between Chinese developed ICIs and imported ICIs. METHODS: A retrospective analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Si, Bai, Hansheng, Zhang, Ling, He, Jiamin, Luo, Xiangru, Wang, Shiyi, Fan, Guangjun, Sun, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399397/ https://www.ncbi.nlm.nih.gov/pubmed/36035942 http://dx.doi.org/10.3389/fcvm.2022.969942

Ejemplares similares

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
por: Jain, P., et al.
Publicado: (2021)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study
por: Zhang, Chuan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

Real-World and Regulatory Perspectives of Artificial Intelligence in Cardiovascular Imaging
por: Wellnhofer, Ernst
Publicado: (2022)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

Editorial: Insights in cardiovascular imaging: 2022
por: Kelle, Sebastian, et al.
Publicado: (2023)

Editorial: Insights in cardiovascular therapeutics 2022—cardiovascular innate immunity
por: Xu, Keman, et al.
Publicado: (2023)

Prognostic Value of Arm Circumference for Cardiac Damage and Major Adverse Cardiovascular Events: A Friend or a Foe? A 2-Year Follow-Up in the Northern Shanghai Study
por: Zheng, Yixing, et al.
Publicado: (2022)

Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases
por: Longoni, Mauro, et al.
Publicado: (2023)

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial
por: Ma, Teng, et al.
Publicado: (2023)

The hemoglobin glycation index predicts the risk of adverse cardiovascular events in coronary heart disease patients with type 2 diabetes mellitus
por: Xu, Shuai, et al.
Publicado: (2022)

Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate
por: Na, Li, et al.
Publicado: (2023)

Editorial: Insights in cardiovascular epidemiology and prevention: 2022
por: Lin, Gen-Min
Publicado: (2023)

Editorial: Case reports in cardiovascular imaging: 2022
por: Karanasos, Antonios, et al.
Publicado: (2023)

Editorial: Insights in general cardiovascular medicine: 2022
por: Acampa, Maurizio, et al.
Publicado: (2023)

Development and validation of a risk prediction model for in-hospital major cardiovascular events in patients hospitalised for acute myocardial infarction
por: Wu, Chaoqun, et al.
Publicado: (2021)

Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021)

Study title: A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use
por: Kim, Mimi M., et al.
Publicado: (2023)

Editorial: Advances in predicting future adverse coronary events: the role of cardiovascular imaging and coronary physiology indices
por: Seitun, Sara, et al.
Publicado: (2023)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

CT-Based Leiden Score Outperforms Confirm Score in Predicting Major Adverse Cardiovascular Events for Diabetic Patients with Suspected Coronary Artery Disease
por: Liu, Zinuan, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Editorial: Case reports in general cardiovascular medicine: 2022
por: Wang, Lijun, et al.
Publicado: (2023)

Editorial: Debates in cardiovascular pharmacology and drug discovery: 2022
por: Xu, Keman, et al.
Publicado: (2023)

Editorial: Insights in cardiovascular biologics and regenerative medicine: 2022
por: Madeddu, Paolo, et al.
Publicado: (2023)

Development and Validation of a Nomogram of In-hospital Major Adverse Cardiovascular and Cerebrovascular Events in Patients With Acute Coronary Syndrome
por: Bo, Xiangwei, et al.
Publicado: (2021)

Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Dregoesc, Mihaela Ioana, et al.
Publicado: (2022)

Association Between Circulating Retinol-Binding Protein 4 and Adverse Cardiovascular Events in Stable Coronary Artery Disease
por: Qian, Ke, et al.
Publicado: (2022)

Cardiovascular mortality trends in Switzerland 1995–2018
por: Sorrentino, Lisa, et al.
Publicado: (2022)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
por: Inno, Alessandro, et al.
Publicado: (2021)

Editorial: Case reports in cardiovascular genetics and systems medicine: 2022
por: Morgan, Neil V.
Publicado: (2023)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Leukocyte Telomere Length Shortening Implies Plaque Instability and Major Adverse Cardiovascular Events in Patients With Angiographically Intermediate Lesions
por: Zhang, Alian, et al.
Publicado: (2022)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

A prediction model for major adverse cardiovascular events in patients with heart failure based on high-throughput echocardiographic data
por: Sun, Qinliang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m2pcnkhgo54j2qk6ibduktref4